Thrombolysis With Recombinant Human Tissue-Type Plasminogen Activator During Instability in Coronary Artery Disease: Effect on Myocardial Ischemia and Need for Coronary Revascularization - TRIC


TRIC was a prospective, randomized, double-blind, placebo-controlled, multicenter trial conducted in Sweden to determine the effect of recombinant tissue-type plasminogen activator (rTPA) in patients with unstable angina and non-Q-wave myocardial infarctions (NQWMIs).